LIU Jia-lin, ZHOU Ting-ting, ZHANG Wei-dong. Advances in biomarkers and stem cell-targeted therapy for hepatocellular carcinomaJ. Acta Pharmaceutica Sinica, 2018,53(5): 709-715. doi: 10.16438/j.0513-4870.2017-1241
Citation: LIU Jia-lin, ZHOU Ting-ting, ZHANG Wei-dong. Advances in biomarkers and stem cell-targeted therapy for hepatocellular carcinomaJ. Acta Pharmaceutica Sinica, 2018,53(5): 709-715. doi: 10.16438/j.0513-4870.2017-1241

Advances in biomarkers and stem cell-targeted therapy for hepatocellular carcinoma

  • Primary hepatocellular carcinoma as the main pathological type of liver cancer is one of the common malignant tumors in our country. Liver cancer stem cells (LCSCs) have the characteristics of multidrug resistance, anti-radiotherapy and high tumorigenicity in addition to the characteristics of stem cells, namely, self-renewal, multi-directional differentiation and unlimited proliferation. Based on the above features, relapse and metastasis often occur after the patients being treated with conventional methods, which results in poor prognosis. Effective treatment targeting LCSCs has the potential to cure hepatocellular carcinoma (HCC) completely. This article reviews the common biomarkers used in identification of LCSCs and development of stem cell-targeted therapy for HCC.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return